UTHR

United Therapeutics Stock Analysis

AI Rating

Good
  • Quality9/10
  • Growth↓ 4/10
  • Momentum↑ 7/10
United Therapeutics sales and earnings growth
UTHR Growth
Neutral
  • Revenue Y/Y↑ 13.50%
  • EPS Y/Y↑ 17.15%
  • FCF Y/Y↑ 24.92%
United Therapeutics gross and profit margin trends
UTHR Profitability
Great
  • Gross margin ↑ 88.60%
  • EPS margin↑ 40.70%
  • ROIC↑ 31.70%
United Therapeutics net debt vs free cash flow
UTHR Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 69.6

United Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗